1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Sprycel is launched in Japan

 
• By Ian Haydock

Bristol-Myers Squibb's Sprycel (dasatinib) has been launched in Japan. The multi-targeted tyrosine kinase inhibitor is indicated for the treatment of imatinib-resistant Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) in the chronic, accelerated or acute (blast) phases, and Ph+ acute lymphoblastic leukaemia (ALL).

Bristol-Myers Squibb's Sprycel (dasatinib) has been launched in Japan. The multi-targeted tyrosine kinase inhibitor is indicated for the treatment of imatinib-resistant Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) in the chronic, accelerated or acute (blast) phases, and Ph+ acute lymphoblastic leukaemia (ALL).

The market entry follows the product's recent inclusion in the national insurance reimbursement tariff. The 20mg tablet is reimbursed at ¥4,565.20 ($47.80) and the 50mg tablet at ¥10,793.30.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

More from Therapeutic Category

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.